Xeris Biopharma reports Annual Meeting voting results; all proposals approved

Xeris Biopharma Holdings, Inc.

Three Class I directors elected: Bormann (57.1M for), Brady (76.5M for), Kong (75.9M for).
Ratification of Ernst & Young as auditor for FY2025: 110.1M for, 0.7M against.
Advisory say-on-pay compensation vote passed: 72.2M for, 5.6M against, 0.9M abstain.
All proposals passed with required votes; no material changes to board or auditor.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.